Mabrix 10 mg/ml (IV Infusion)

Indications

• Non-Hodgkin’s Lymphoma (NHL) treatment
• Chronic Lymphocytic Leukemia (CLL) treatment
• Rheumatoid Arthritis (RA) treatment
• Granulomatosis with Polyangiitis (GPA) treatment
• Pemphigus Vulgaris (PV) treatment

Pharmacology

• Monoclonal IgG1 kappa antibody
• CD20 antigen targeting
• Approximate molecular weight: 145 kD
• Binding affinity for CD20 antigen: 8.0 nM

Dosage & Administration

• Intravenous infusion only
• Different rates for first and subsequent infusions
• Recommended doses for different indications
• Premedication necessary before each infusion
• Dosage based on patient's condition and age

Interaction

• No formal drug interaction studies performed
• No alteration of systemic exposure to specific drugs

Contraindications

• Known hypersensitivity to Rituximab or its components

Side Effects

• Reactivation of hepatitis B virus
• Infusion-related reactions
• Mucocutaneous reactions
• Progressive Multifocal Leukoencephalopathy (PML)
• Tumor Lysis Syndrome (TLS)
• Serious infections

Pregnancy & Lactation

• Potential fetal harm
• Adverse developmental outcomes in infants
• Adverse outcomes regardless of maternal health or medication use
• Limited data on presence in human milk
• Excretion in low concentrations in human breast milk

Precautions & Warnings

• Severe infusion-related reactions
• Severe mucocutaneous reactions
• Progressive Multifocal Leukoencephalopathy (PML)
• Tumor Lysis Syndrome (TLS)
• Serious infections

Therapeutic Class

• Cytotoxic immunosuppressants

Storage Conditions

• Refrigeration at 2°C-8°C
• Protection from light
• Keep out of reach of children

Related Brands

• Ritumab 10 mg/ml (IV Infusion) - drug-international-ltd